Recurrent Pregnancy Loss Medical Services in China

Recurrent Pregnancy Loss (RPL), defined as two or more consecutive clinical pregnancy losses before 20 weeks of gestation, is a complex and emotionally devastating condition affecting individuals and couples seeking to build a family. While historically defined as three or more losses, contemporary guidelines—including those from the American College of Obstetricians and Gynecologists (ACOG) and the European Society of Human Reproduction and Embryology (ESHRE)—recognize that evaluation should begin after two losses due to the significant psychological burden and increased likelihood of an underlying etiology. Pathogenesis is multifactorial and often idiopathic; however, identifiable causes include parental chromosomal abnormalities (e.g., balanced translocations), uterine structural anomalies (e.g., septate uterus, intrauterine adhesions), endocrine disorders (e.g., uncontrolled thyroid disease, luteal phase defect, poorly managed diabetes), autoimmune factors (notably antiphospholipid syndrome), thrombophilias (inherited or acquired), and emerging evidence implicating chronic endometritis, sperm DNA fragmentation, and immunologic dysregulation at the maternal-fetal interface. Epidemiologically, RPL affects approximately 1–2% of couples attempting conception, with prevalence rising to ~5% when including women reporting two losses. Risk factors span genetic (advanced maternal age >35, paternal age >40), anatomical (congenital Müllerian anomalies, fibroids), lifestyle (smoking, excessive caffeine, obesity, substance use), environmental (occupational toxin exposure), and comorbid medical conditions (PCOS, celiac disease, chronic hypertension). Importantly, up to 50–75% of cases remain unexplained after standard evaluation—highlighting the need for individualized, multidisciplinary care in reproductive medicine. The psychosocial impact is profound: patients frequently experience grief, anxiety, depression, marital strain, social isolation, and diminished self-worth. Many report feeling stigmatized or dismissed by healthcare providers, leading to treatment delays and reduced adherence. Quality of life metrics consistently show impairments comparable to those seen in chronic illnesses such as cancer or heart failure—underscoring RPL not merely as a reproductive issue but as a holistic health concern requiring integrated psychological, endocrinologic, immunologic, and surgical expertise. Early referral to specialized reproductive medicine departments enables comprehensive workup—including karyotyping, pelvic imaging (3D ultrasound, hysterosalpingography, hysteroscopy), hormonal profiling, thrombophilia screening, and immune markers—and facilitates timely, evidence-based interventions tailored to each patient’s unique profile.

Recurrent Pregnancy Loss (RPL), defined as two or more clinically recognized pregnancy losses prior to 20 weeks’ gestation, affects approximately 1–2% of couples attempting conception. A comprehensive evaluation by a reproductive medicine specialist is essential to identify potentially modifiable and non-modifiable contributors. The etiology of RPL is multifactorial, with identifiable causes present in roughly 50–75% of cases after thorough investigation.

Common causes include parental chromosomal abnormalities—most frequently balanced translocations or inversions—which occur in 2–5% of RPL patients and predispose to embryonic aneuploidy. Uterine anatomical anomalies account for 10–15% of cases; these include congenital malformations (e.g., septate uterus, the most common müllerian anomaly associated with RPL), acquired lesions (e.g., intrauterine adhesions, submucosal fibroids, endometrial polyps), and cervical insufficiency. Endocrine disorders are implicated in 17–20% of RPL cases: uncontrolled thyroid disease (particularly subclinical or overt hypothyroidism with elevated TSH and/or positive thyroid peroxidase antibodies), poorly managed diabetes mellitus (HbA1c >6.5%), luteal phase defect (inadequate progesterone production or endometrial response), and hyperprolactinemia. Thrombophilic conditions—both inherited and acquired—contribute significantly: antiphospholipid syndrome (APS), the most prevalent acquired thrombophilia in RPL, is diagnosed by persistent presence (>12 weeks apart) of lupus anticoagulant, anticardiolipin IgG/IgM, or anti-β2-glycoprotein I antibodies. Inherited thrombophilias (e.g., factor V Leiden, prothrombin G20210A mutation, protein C/S or antithrombin deficiency) confer more modest risk and remain controversial in isolation without APS.

Triggers of pregnancy loss in susceptible individuals often involve acute physiological stressors: severe maternal infection (e.g., listeriosis, cytomegalovirus, parvovirus B19), major surgery or trauma during early gestation, abrupt discontinuation of luteal support in assisted reproductive technology cycles, or uncontrolled systemic inflammation (e.g., active lupus flares). Suboptimal embryo implantation due to dyssynchronous endometrial development—often linked to aberrant steroid hormone signaling or chronic endometritis (diagnosed via CD138+ plasma cell immunohistochemistry)—may serve as a functional trigger even in anatomically normal uteri.

Genetic factors extend beyond parental karyotype. Embryonic aneuploidy—present in ≥50% of sporadic miscarriages and up to 70% of losses in women aged ≥35—remains the single largest contributor to RPL, particularly with advancing maternal age. Polymorphisms in genes regulating folate metabolism (e.g., MTHFR C677T), coagulation (e.g., PAI-1 4G/5G), immune tolerance (e.g., HLA-G, KIR genotypes), and oxidative stress response may modulate individual susceptibility but lack consistent predictive utility in clinical practice and are not routinely tested.

Environmental and lifestyle risk factors are increasingly recognized. Maternal smoking (>10 cigarettes/day) increases RPL risk by 40–60% through placental hypoxia, oxidative DNA damage, and impaired trophoblast invasion. Chronic alcohol consumption (>2 standard drinks/week) and illicit drug use (e.g., cocaine, methamphetamine) disrupt endocrine homeostasis and vascular integrity. Obesity (BMI ≥30 kg/m²) promotes chronic low-grade inflammation, insulin resistance, and altered adipokine profiles that impair oocyte quality and decidualization. Environmental toxins—including occupational exposure to organic solvents, pesticides (e.g., organochlorines), heavy metals (lead, mercury), and endocrine-disrupting chemicals (e.g., bisphenol A, phthalates)—are associated with increased miscarriage rates via epigenetic dysregulation, mitochondrial dysfunction, and hormonal interference. Advanced paternal age (>40–45 years) correlates with elevated de novo sperm DNA fragmentation and point mutations, contributing to embryonic genomic instability.

Psychosocial stress, while not a direct cause, may exacerbate underlying pathophysiology through hypothalamic-pituitary-adrenal axis activation, resulting in elevated cortisol and catecholamines that impair uterine blood flow and immune modulation. However, evidence linking stress alone to RPL remains inconclusive. Comprehensive management requires integration of genetic counseling, endocrine optimization, thrombophilia screening, hysteroscopic evaluation, infectious workup when indicated, and personalized lifestyle modification—underscoring the necessity of multidisciplinary care within reproductive medicine.

Recurrent Pregnancy Loss (RPL), defined as two or more clinically recognized pregnancy losses prior to 20 weeks’ gestation, is a complex reproductive disorder managed primarily within the Department of Reproductive Medicine. Unlike sporadic miscarriage—which affects approximately 10–15% of clinically confirmed pregnancies—RPL affects 1–2% of couples attempting conception and warrants systematic evaluation due to its multifactorial etiology, including genetic, anatomical, endocrine, immunologic, thrombophilic, and environmental contributors. Importantly, RPL is not a disease per se but a clinical sign indicating underlying pathophysiology requiring thorough investigation.

Early symptoms of RPL are typically absent prior to pregnancy recognition. Most affected individuals present only after experiencing repeated pregnancy failures; thus, there are no prodromal or preconception signs predictive of RPL. However, certain risk-associated features may emerge during preconception counseling: unexplained infertility, advanced maternal age (>35 years), known parental balanced chromosomal rearrangements (e.g., Robertsonian or reciprocal translocations), history of uterine surgery (e.g., metroplasty), or personal/family history of venous thromboembolism or autoimmune disorders. These are not symptoms but rather epidemiologic and clinical red flags prompting earlier referral.

Typical symptoms manifest exclusively during pregnancy and reflect the natural course of embryonic or fetal demise. The most common presentation is vaginal bleeding—often painless, light to moderate, and occurring between 6–12 weeks’ gestation—accompanied by passage of tissue or clots. Crampy, intermittent lower abdominal or pelvic discomfort frequently co-occurs, mimicking normal early pregnancy sensations but escalating in intensity or duration. In missed miscarriage—a frequent subtype in RPL—patients may report diminishing or absent pregnancy symptoms (e.g., reduced breast tenderness, fading nausea) without overt bleeding or pain, leading to delayed diagnosis via ultrasound. Less commonly, patients experience sudden, severe pelvic pain with hemodynamic instability, suggesting inevitable or incomplete miscarriage with significant hemorrhage or, rarely, cervical insufficiency presenting as painless dilation and expulsion in the second trimester (14–20 weeks).

Accompanying symptoms are generally nonspecific and often reflect psychological sequelae rather than organic pathology. Persistent anxiety surrounding conception, hypervigilance regarding early pregnancy symptoms, sleep disturbances, and anticipatory grief are prevalent. Some patients report chronic pelvic discomfort attributed to underlying uterine anomalies (e.g., septate uterus causing dysmenorrhea or recurrent implantation failure), though such symptoms are not directly causative of RPL. Mild, recurrent luteal phase defects may manifest as shortened menstrual cycles (<24 days), premenstrual spotting, or elevated basal body temperature patterns inconsistent with sustained progesterone effect—but these are subtle and require objective hormonal assessment for confirmation.

Complications extend beyond reproductive morbidity. Psychologically, RPL confers significantly elevated risks of clinical depression (prevalence ~30–50%), generalized anxiety disorder, post-traumatic stress symptoms, marital strain, and sexual dysfunction. Physiologically, recurrent uterine instrumentation (e.g., multiple dilation and curettage procedures) increases risks of intrauterine adhesions (Asherman syndrome), chronic endometritis, and subsequent implantation failure or placental abnormalities. Untreated inherited thrombophilias (e.g., factor V Leiden, prothrombin G20210A mutation) may predispose to late obstetric complications in future viable pregnancies—including placental infarction, fetal growth restriction, preeclampsia, and stillbirth. Autoimmune-mediated RPL—particularly associated with antiphospholipid syndrome (APS)—carries long-term vascular risks, including cerebrovascular events and valvular heart disease, necessitating lifelong monitoring.

Diagnosis relies on rigorous exclusion and stratified testing. Initial evaluation includes detailed obstetric, medical, surgical, and family histories; karyotyping of both partners; transvaginal 3D ultrasound or saline infusion sonohysterography (SIS) to assess uterine morphology; and assessment of ovarian reserve (AMH, AFC, day-3 FSH/E2). Endocrine evaluation encompasses thyroid function tests (TSH, free T4, anti-TPO antibodies), prolactin, HbA1c or oral glucose tolerance test, and luteal-phase serum progesterone (measured 7 days post-ovulation). Immunologic workup centers on APS criteria: lupus anticoagulant (by dilute Russell viper venom time and confirmatory assays), anticardiolipin IgG/IgM, and anti-β2-glycoprotein I IgG/IgM—requiring two positive tests ≥12 weeks apart. Thrombophilia screening is selective—not routine—and reserved for those with personal/family history of thrombosis or late pregnancy loss. Endometrial biopsy for chronic endometritis (CD138 immunohistochemistry) and microbiologic testing (e.g., PCR for Mycoplasma hominis, Ureaplasma) are increasingly incorporated given emerging evidence linking subclinical endometritis to RPL. Preimplantation genetic testing for aneuploidy (PGT-A) may be considered in IVF cycles following recurrent aneuploid losses.

Differential diagnosis is critical to avoid misattribution. Sporadic miscarriage must be distinguished from true RPL using strict definition: ≥2 losses confirmed by ultrasound or histopathology—not biochemical pregnancies (isolated elevations of β-hCG without gestational sac). Other conditions mimicking RPL include parental gonadal mosaicism (undetectable on standard karyotype), subclinical embryonic aneuploidy due to advanced paternal age or sperm DNA fragmentation (assessed via SCSA or TUNEL assay), and undiagnosed celiac disease (associated with nutrient malabsorption and immune dysregulation). Anatomic mimics include arcuate or bicornuate uterus—often asymptomatic but potentially contributing to second-trimester loss—versus septate uterus, which carries the highest RPL risk among Müllerian anomalies. Endocrine differentials include uncontrolled diabetes mellitus, hyperprolactinemia-induced anovulation, and non-classical congenital adrenal hyperplasia (elevated 17-OHP, androstenedione). Immunologically, systemic lupus erythematosus (SLE) without antiphospholipid antibodies rarely causes RPL, whereas APS remains the only treatable autoimmune cause. Finally, iatrogenic factors—including inappropriate use of ovulation induction agents or suboptimal embryo transfer technique in ART cycles—must be scrutinized before labeling idiopathic RPL, which persists in ~50% of thoroughly evaluated cases. Comprehensive, individualized assessment remains the cornerstone of effective management.

Recurrent Pregnancy Loss (RPL), defined as two or more clinically documented pregnancy losses prior to 20 weeks’ gestation, affects approximately 1–5% of couples attempting conception. A comprehensive, evidence-based evaluation is essential before initiating treatment, as RPL has heterogeneous etiologies—including parental chromosomal abnormalities (e.g., balanced translocations), uterine anatomic anomalies (e.g., septate uterus), endocrine disorders (e.g., uncontrolled thyroid disease, luteal phase defect, or poorly managed diabetes), autoimmune factors (notably antiphospholipid syndrome [APS]), thrombophilias (inherited or acquired), and emerging contributors such as sperm DNA fragmentation and endometrial immune dysregulation. In up to 50% of cases, no definitive cause is identified—termed unexplained RPL—necessitating individualized, supportive, and empiric management strategies.

Conservative treatment forms the cornerstone of RPL care, particularly in unexplained cases or when no modifiable risk factors are present. This includes preconception counseling emphasizing lifestyle optimization: smoking cessation, alcohol abstinence, caffeine restriction (<200 mg/day), weight normalization (BMI 18.5–24.9 kg/m²), and regular moderate exercise. Psychological support is integral; cognitive-behavioral therapy (CBT) and peer-led support groups significantly reduce anxiety and depression scores, which correlate with improved live birth rates in longitudinal studies. Serial early ultrasound monitoring (transvaginal at 6–7 weeks, then every 1–2 weeks until fetal viability) provides timely reassurance and reduces uncertainty-related distress. Empiric progesterone supplementation (200–400 mg micronized vaginal progesterone daily from ovulation or positive pregnancy test until 12 weeks) is recommended for women with prior unexplained RPL, based on the PRISM and PROMISE trials demonstrating modest but statistically significant improvement in live birth rates (RR 1.08–1.15). Folic acid (400–800 µg/day) and vitamin D repletion (target serum 25(OH)D >30 ng/mL) are universally advised due to their roles in genomic stability and immunomodulation.

Pharmacologic interventions are targeted to specific diagnoses. For APS, low-dose aspirin (75–100 mg/day) initiated preconception plus prophylactic enoxaparin (40 mg SC once daily) from positive pregnancy test until delivery is standard; this regimen reduces miscarriage recurrence by ~70% compared to aspirin alone. Thyroid autoimmunity (elevated TPO antibodies without overt dysfunction) may warrant levothyroxine titration to maintain TSH <2.5 mIU/L, though evidence for live birth benefit remains mixed. In luteal phase insufficiency confirmed by mid-luteal serum progesterone <10 ng/mL or inadequate endometrial biopsy dating, intramuscular or vaginal progesterone is indicated. Metformin is used adjunctively in PCOS-associated RPL with insulin resistance (HOMA-IR ≥2.5), improving endometrial receptivity and reducing early loss. Emerging agents under investigation include intralipid infusions and granulocyte colony-stimulating factor (G-CSF) for presumed endometrial immune dysfunction, though current data are insufficient for routine recommendation outside clinical trials.

Surgical treatment is reserved for structural uterine pathology. Hysteroscopic metroplasty is the gold-standard intervention for a septate uterus—the most common congenital anomaly linked to RPL—with live birth rates increasing from ~40% to >80% post-correction. Adhesiolysis (via hysteroscopic lysis of intrauterine adhesions) restores endometrial surface area and vascularization in Asherman syndrome. Myomectomy is indicated for submucosal or large intramural fibroids (>4 cm) distorting the cavity, preferably performed laparoscopically or via hysteroscopy to minimize uterine scarring. All surgical procedures require postoperative hormonal suppression (e.g., combined oral contraceptives or GnRH agonist for 2–3 months) followed by endometrial assessment (saline infusion sonohysterography or hysteroscopy) prior to conception attempt.

Treatment in China offers distinct advantages rooted in integrated reproductive medicine infrastructure. Major academic centers (e.g., Peking University Third Hospital, Shanghai Jiao Tong University Affiliated Renji Hospital) operate multidisciplinary RPL clinics combining reproductive endocrinology, clinical genetics, immunology, hematology, and psychology—ensuring seamless diagnostic coordination and rapid turnaround for karyotyping, thrombophilia panels, and endometrial immune profiling (e.g., NK cell subsets, uNK density quantification via CD56+ immunohistochemistry). China’s national health system enables cost-effective access to advanced diagnostics: whole-exome sequencing for embryonic aneuploidy analysis, high-resolution hysterosalpingography with 3D reconstruction, and standardized antiphospholipid antibody testing per Sydney criteria. Traditional Chinese Medicine (TCM) is frequently integrated as adjunctive conservative therapy; randomized trials from Guangzhou Medical University demonstrate that acupuncture combined with progesterone improves implantation rates and reduces inflammatory cytokines (IL-6, TNF-α) in RPL patients. Moreover, China’s robust assisted reproductive technology (ART) ecosystem allows timely transition to IVF with preimplantation genetic testing for aneuploidy (PGT-A) or structural rearrangements (PGT-SR) when indicated—reducing time-to-pregnancy and emotional burden.

Post-treatment recovery emphasizes continuity and prevention. Patients are advised to wait 2–3 menstrual cycles after surgical correction or completion of anticoagulation therapy before attempting conception, allowing endometrial healing and hormonal stabilization. Serial monitoring includes first-trimester serial β-hCG (every 48 hours initially), progesterone levels (if supplemented), and transvaginal ultrasound at 6, 8, and 10 weeks to assess embryonic growth and cardiac activity. Postpartum, long-term follow-up addresses cardiovascular risk mitigation (given APS or thrombophilia), thyroid surveillance, and psychosocial resilience building. Couples are counseled that even with optimal management, the cumulative live birth rate after three losses remains ~60–70%; thus, realistic expectations and shared decision-making remain central. Finally, male factor evaluation—including semen analysis, sperm DNA fragmentation testing (SCD assay or TUNEL), and lifestyle counseling—is routinely incorporated, reflecting the growing recognition of paternal contributions to RPL pathogenesis.